Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Avis Budget and Hertz Global slide even further after the crowded short trade drama (SeekingAlpha) +++ HERTZ Aktie +3,48%

MODERNA Aktie

 >MODERNA Aktienkurs 
46.475 EUR    -2.2%    (TradegateBSX)
Ask: 46.32 EUR / 2100 Stück
Bid: 46.215 EUR / 2100 Stück
Tagesumsatz: 10344 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MODERNA Aktie über LYNX handeln
>MODERNA Performance
1 Woche: +3,2%
1 Monat: +7,4%
3 Monate: +7,1%
6 Monate: +104,3%
1 Jahr: +110,5%
laufendes Jahr: +78,3%
>MODERNA Aktie
Name:  MODERNA INC. DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US60770K1079 / A2N9D9
Symbol/ Ticker:  0QF (Frankfurt) / MRNA (NASDAQ)
Kürzel:  FRA:0QF, ETR:0QF, 0QF:GR, NASDAQ:MRNA
Index:  S&P500
Webseite:  https://www.modernatx.com..
Profil:  Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary function centers on creating innovative therapeutics an..
>Volltext..
Marktkapitalisierung:  18366.69 Mio. EUR
Unternehmenswert:  14524.34 Mio. EUR
Umsatz:  1656.09 Mio. EUR
EBITDA:  -2435.58 Mio. EUR
Nettogewinn:  -2404.06 Mio. EUR
Gewinn je Aktie:  -6.19 EUR
Schulden:  1111.73 Mio. EUR
Liquide Mittel:  2211.53 Mio. EUR
Operativer Cashflow:  -1595.6 Mio. EUR
Bargeldquote:  2.92
Umsatzwachstum:  -47.05%
Gewinnwachstum:  30.15%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MODERNA
Letzte Datenerhebung:  23.04.26
>MODERNA Kennzahlen
Aktien/ Unternehmen:
Aktien: 394.94 Mio. St.
Frei handelbar: 91.46%
Rückkaufquote: -0.16%
Mitarbeiter: 4700
Umsatz/Mitarb.: 0.35 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -17.23%
Bewertung:
KGV: -
KGV lG: -
KUV: 10.95
KBV: 2.48
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 44.29%
Gewinnmarge: -145.16%
Operative Marge: -158.13%
Managementeffizenz:
Gesamtkaprendite: -21.31%
Eigenkaprendite: -28.87%
>MODERNA Peer Group
 
22.04.26 - 19:00
European Commission Approves MRNA′s COVID-19-Influenza Combo Shot (Zacks)
 
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines....
22.04.26 - 17:03
Moderna starts late-stage trial for bird flu vaccine (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 01:06
Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate (Accesswire)
 
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / Apri......
21.04.26 - 17:00
Moderna Receives EU Approval for Influenza and COVID-19 Combination Vaccine for Older Adults (AAStocks)
 
Moderna (MRNA.US) said on Tuesday that the European Commission has granted marketing authorization for a combination vaccine indicated for the prevention of influenza and COVID-19 in adults aged 50 and above.(to/s)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese versio......
21.04.26 - 16:33
Moderna granted EU nod for combined COVID-19 and flu vaccine (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.04.26 - 16:06
Moderna, Inc.: Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting (Accesswire)
 
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on......
21.04.26 - 15:54
Moderna, Inc.: Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna′s mRNA Combination Vaccine Against Influenza and COVID-19 (Accesswire)
 
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will be made available in the European Union, s......
21.04.26 - 13:06
Moderna, Inc.: Moderna to Present at Upcoming Conferences in May 2026 (Accesswire)
 
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:BofA Securities 2026 Healthcare Conf......
19.04.26 - 06:37
Sanofi′s Nuvaxovid Shows Superior Tolerability Over Moderna′s MNEXSPIKE In COMPARE Study (AFX)
 
PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest mRNA v......
17.04.26 - 21:06
Moderna, Inc.: Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting (Accesswire)
 
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ......
16.04.26 - 18:18
Cómo Anthropic descubrió que Mythos era demasiado peligroso (Bloomberg)
 
Los propios expertos de la empresa de IA advirtieron que Mythos podría vulnerar los sistemas que sustentan gran parte de la computación moderna. Bancos y agencias gubernamentales se apresuran a evaluar la amenaza....
15.04.26 - 13:06
Moderna, Inc.: Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 (Accesswire)
 
CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report i......
09.04.26 - 07:48
Moderna eyes international markets as growth driver, says Bank of America (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
08.04.26 - 16:30
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.26 - 14:06
Life Sciences Ontario Welcomes New Board Members in 2026 Following Annual General Meeting (Business Wire)
 
TORONTO--(BUSINESS WIRE)--Life Sciences Ontario (LSO) is pleased to announce the appointment of four distinguished leaders to its Board of Directors, following its Annual General Meeting on March 25, 2026. The newly appointed board members are: Amelia Swanson, vice-president, Medtech Canada Dave Smardon, president and CEO, Bioenterprise Canada Leslie Madden, senior director, head of government affairs and policy, Moderna Canada Melody Greaves, executive director and vice-president, government relations, Canadian Nuclear Isotope Council “We are delighted to welcome such highly qualified professionals to the Board,” said Dr. Jason Field, president and CEO, Life Sciences Ontario. “They each bring exceptional experience and a demonstrated ability to drive innovation, shape policy, and build meaningful partnerships. We look forward to working together to advance Ontario's life sciences sector and strengthen its global competitiveness.” During the Annual General Meeting, LSO also presented its 2025 Ann...
07.04.26 - 00:06
Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 (Accesswire)
 
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010......
03.04.26 - 17:48
Top Moderna Shareholders (Investopedia)
 
Um den gesamten Artikel unter investopedia.com zu lesen, klicken Sie bitte auf die Überschrift...
30.03.26 - 16:48
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next (24/7 Wall St.)
 
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same period, still below its pandemic peak. Novavax (NASDAQ: NVAX) has lost 95.3% in five years. The central question for any investor holding or considering ... 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next The post 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next appeared first on 24/7 Wall St.....
30.03.26 - 08:31
Moderna vor entscheidender Bewährungsprobe (LYNX)
 
Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung....
28.03.26 - 00:45
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
 
Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior day's close....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Quod cito fit, cito perit - Was schnell entsteht, auch schnell vergeht. - Nomen Nescio
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!